MERIT acquires OSOD to enhance ophthalmic drug development

(Image Credit: AdobeStock)

MERIT, a global clinical trial endpoint and technology services provider, announced its acquisition of OSOD, LLC. OSOD’s 30 years of ophthalmic preclinical drug development has helped advance several ophthalmic therapies from preclinical research to market approval, including Lucentis, Eylea, and Susvimo.

"MERIT is delighted to welcome OSOD to our family,” Yijun Huang, CEO of MERIT, said. “This acquisition represents a significant milestone in our mission to advance drug development and deliver life-changing therapies to patients worldwide. Together, we will set new standards in the industry and drive forward the future of medicine."

The acquisition will further MERIT’s service offerings, allowing for a seamless transition from preclinical to clinical phase of drug development.

"OSOD has always been committed to excellence in early-stage ophthalmology research. Joining forces with MERIT allows us to extend our impact and contribute to the entire drug development continuum,” Christopher Murphy, CEO of OSOD, said. “Importantly, the entire management team, employees and our distributed network of experts in vision science and drug development remain committed to advancing the impact of OSOD in ocular drug development. We look forward to leveraging the resources and capabilities of MERIT to the benefit of our clients in bringing much needed therapeutics to the marketplace to benefit patients. We look forward to a collaborative and innovative future.”

Reference:

1. MERIT Acquires OSOD, Expanding Capabilities in Early-Stage Drug Development. MERIT. Accessed February 3, 2025. https://www.einpresswire.com/article/778019984/merit-acquires-osod-expanding-capabilities-in-early-stage-drug-development